|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Incyte (INCY) distributes its key drug, Jakafi, through its own network of specialty pharmacy providers and wholesalers in US markets.
Incyte’s (INCY) product portfolio includes targeted therapies and immunotherapies for oncology as well as non-oncology products.
Topas Therapeutics GmbH, which last year sold venture firms on its technology for developing autoimmune-disease treatments, has now won over a large pharmaceutical company.